Tandem Diabetes Care Inc
NASDAQ:TNDM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Tandem Diabetes Care Inc
Total Liabilities & Equity
Tandem Diabetes Care Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Tandem Diabetes Care Inc
NASDAQ:TNDM
|
Total Liabilities & Equity
$881.1m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
22%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Liabilities & Equity
$43.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Total Liabilities & Equity
$13.7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Liabilities & Equity
$47.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Liabilities & Equity
$86.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Liabilities & Equity
$20.5B
|
CAGR 3-Years
16%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
Tandem Diabetes Care Inc
Glance View
Tandem Diabetes Care Inc., a prominent figure in the healthcare sector, has carved out a notable niche with its innovative diabetes management solutions. Founded in 2006 and headquartered in San Diego, California, the company has become a leader in providing advanced insulin pump technologies. Central to Tandem’s business model is their flagship product, the t:slim X2 Insulin Pump, a sleek and user-friendly device praised for its ease of use and functionality. Through meticulous engineering and design, Tandem has positioned itself at the forefront of modern diabetes management by enhancing user experience and integrating advanced technologies such as continuous glucose monitoring (CGM) compatibility, making diabetes care more dynamic and responsive. Revenue for Tandem Diabetes Care primarily flows from the sale of these insulin pumps, along with associated supplies and accessories, which are crucial for ongoing diabetes management. The company also generates income through software and technology upgrades. By offering a subscription-based model, Tandem ensures steady revenue from the continual acquisition of consumables and technology updates, fostering customer loyalty and long-term engagement. Their commitment to innovation and patient-centric solutions has not only allowed them to tap into a growing market of diabetes patients seeking improved quality of life but has also strengthened their competitive edge in a rapidly evolving healthcare landscape.
See Also
What is Tandem Diabetes Care Inc's Total Liabilities & Equity?
Total Liabilities & Equity
881.1m
USD
Based on the financial report for Dec 31, 2025, Tandem Diabetes Care Inc's Total Liabilities & Equity amounts to 881.1m USD.
What is Tandem Diabetes Care Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
22%
Over the last year, the Total Liabilities & Equity growth was -9%. The average annual Total Liabilities & Equity growth rates for Tandem Diabetes Care Inc have been -6% over the past three years , 4% over the past five years , and 22% over the past ten years .